Koers Vital Therapies Inc Nasdaq
Aandelen
US92847R1041
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 113 mln. 106 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -93 mln. -87,06 mln. | Nettowinst (verlies) 2025 * | -104 mln. -97,36 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | 33,12 mln. 31 mln. | Nettoschuld 2025 * | 55,55 mln. 52 mln. | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-1,28
x | K/w-verhouding 2025 * |
-1,27
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 92,28% |
Recentste transcriptie over Vital Therapies Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Daniel Vitt
CEO | Chief Executive Officer | 55 | 01-01-17 |
Glenn Whaley
DFI | Director of Finance/CFO | 56 | 01-12-19 |
Hella Kohlhof
CTO | Chief Tech/Sci/R&D Officer | 51 | 01-01-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Barclay Phillips
BRD | Director/Board Member | 61 | 19-11-19 |
Tamar Howson
BRD | Director/Board Member | 75 | 11-10-19 |
Jörg Neermann
BRD | Director/Board Member | 57 | 01-04-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-3,46% | 102 mld. | |
+1,41% | 96,09 mld. | |
+2,13% | 22,28 mld. | |
-15,84% | 21,4 mld. | |
-9,14% | 18,14 mld. | |
-39,98% | 17,02 mld. | |
-14,65% | 16,09 mld. | |
+4,39% | 13,83 mld. | |
+31,35% | 11,97 mld. |